Rare disease drove two women on a mission to change FDA drug review process

19 July 2020 - Melissa Goetz and Lindsey Sutton are campaigning to improve the US drug review process for rare diseases. ...

Read more →

Dicerna receives rare paediatric disease designation from U.S. FDA for nedosiran for the treatment of primary hyperoxaluria

18 June 2020 - Dicerna Pharmaceuticals today announced that the U.S. FDA has granted rare paediatric disease designation for nedosiran, ...

Read more →

Rare disease therapy development and access remain top FDA priorities during COVID-19

11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these ...

Read more →

Clarity Pharmaceuticals announces that the US FDA grants rare paediatric disease designation to Copper Cu 67 sartate for the treatment of neuroblastoma

3 June 2020 - Clarity Pharmaceuticals is pleased to announce that the U.S. FDA has granted rare paediatric disease designation to ...

Read more →

Gilead declines 'rare disease' status for experimental coronavirus drug

25 March 2020 - In a surprising turnabout, drugmaker Gilead Sciences asked the FDA on Wednesday to rescind orphan status ...

Read more →

Orphan Technologies receives rare paediatric disease designation from FDA for OT-58 to treat cystathionine B-synthase deficiency homocystinuria

26 March 2020 - Orphan Technologies today announced that OT-58 for the treatment of cystathionine beta synthase deficiency homocystinuria has ...

Read more →

Rare Disease Day 2020: FDA continues important work on treatments for rare diseases

21 February 2020 - As leaders of the FDA, every day we see the unwavering commitment of our agency in working ...

Read more →

After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets

12 February 2020 - For years, hospitals and clinics have used an injectable medicine called dehydrated alcohol to treat such ...

Read more →

ProQR receives rare paediatric disease designation from FDA for QR-421a

30 January 2020 - Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 ...

Read more →

FDA harnesses technology and collaboration to support rare disease product development

17 January 2020 - Announcing an orphan drug technology modernisation effort and the 2020 FDA Rare Disease Day meeting. ...

Read more →

Does an orphan drug policy make a difference in access? A comparison of Canada and Australia.

2 January 2020 - Canada has been discussing whether to implement an orphan drug policy for more than 25 years. Recently, ...

Read more →

Vertex announces European Commission approval for Kalydeco (ivacaftor) in infants with cystic fibrosis ages 6 months to less than 12 months with certain mutations in the CFTR gene

10 December 2019 - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic ...

Read more →

Our drug policy often prioritises eliminating rare disease. One researcher asks: Is that the right goal?

26 November 2019 - Dr. Peter Bach wants to turn the entire philosophical underpinnings of America’s health care system upside ...

Read more →

FDA admits it goofed when granting orphan status to an opioid addiction treatment

8 November 2019 - In an unusual move, the FDA has acknowledged a mistake and revoked orphan drug status for ...

Read more →

Vertex announces EMA marketing authorisation application validation for VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination treatment in cystic fibrosis

31 October 2019 - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages ...

Read more →